

CIRM Funded Clinical Trials

Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma

Disease Area:	Brain Cancer
Investigator:	Christine Brown
Institution:	City of Hope
CIRM Grant:	CLIN2-10248 (Pre-Active)
Award Value:	\$12,753,854
Trial Sponsor:	Beckman Research Institute of City of Hope
Trial Stage:	Phase 1
Trial Status:	Recruiting
Targeted Enrollment:	135
ClinicalTrials.gov ID:	NCT02208362



Christine Brown

Details:

A team at the City of Hope led by Dr. Christine Brown is pursuing a Phase 1 trial targeting an aggressive brain cancer called malignant glioma. City of Hope will re-engineer a patient's immune system central memory T cells (TCM cells) to express chimeric antigen receptors (CAR). These CAR-T cells will recognize a molecular marker on the surface of glioma cancer stem cells and kill the tumors. Dr. Brown's award to pursue CAR-T therapy for solid cancers comes at an exciting and opportune time with the recent U.S. Food and Drug Administration (FDA) approval of the first CAR-T therapy, called Kymriah, for patients with acute lymphoblastic leukemia, a deadly form of blood cancer.

Design:

Non-randomized, open-label treatment.

Goal:

Determine safety, feasibility, and efficacy.

Updates:

This study is currently enrolling and treating participants.

News Releases:

City of Hope Scientist Christine Brown Receives \$12.8M Grant from CIRM to Fund Trial for Brain Cancer

[Contact Trial Sponsor](#)

Source URL: <http://www.cirm.ca.gov/clinical-trial/phase-i-study-chimeric-antigen-receptor-engineered-central-memory-t-cells-treatment-o>